Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The use of metformin pre-treatment and co-administration was recently proposed in infertile
women affected by polycystic ovary syndrome (PCOS) treated with gonadotropins.
Data from meta-analyses showed that metformin administration significantly reduced the
stimulation length and the total dose of gonadotropins used in PCOS women undergoing
gonadotropins stimulation for non in-vitro fertilization (IVF) cycles. On the other hand, in
IVF cycles metformin was demonstrated to significantly reduce the ovarian hyperstimulation
syndrome (OHSS) rate in infertile patients with PCOS treated with gonadotropins.
The metformin regulating effect on the ovarian response was also observed in a randomized
controlled trial (RCT) on young non-obese insulin-resistant women with PCOS receiving
gonadotropins for mono-ovulation induction. In particular, metformin increased the
mono-ovulatory cycles, the duration of stimulation and the amount of gonadotropins used,
while it reduced the number of dominant follicles and the estradiol (E2) levels.
The aim of the present study was to evaluate the effect of metformin administration in high
responder PCOS patients undergoing gonadotropins ovarian stimulation for IVF cycles.